Core Insights - Cibus, Inc. announced that two of its disease resistance trait products for canola have been designated as not regulated by the USDA-APHIS, allowing for unrestricted product development in the U.S. [1][2] Regulatory Developments - The USDA-APHIS confirmed that the products developed using Cibus' Rapid Trait Development System™ (RTDS®) do not meet the definition of a "regulated article," enabling Cibus to advance product development without regulatory restrictions [2][3] - The designation aligns with evolving regulatory frameworks globally, including the EU's recent endorsement of regulations for plants developed by New Genomic Techniques (NGTs), which will treat certain gene-edited products similarly to conventional varieties [3][4] Product Features and Benefits - Cibus' Sclerotinia resistance trait in canola provides multiple modes of action, helping farmers improve yields and reduce reliance on fungicides, which are necessary for controlling Sclerotinia sclerotiorum, a significant pathogen that can reduce canola yields by 7-15% [4][5] - The company anticipates that the application of its traits will extend to other crops like soybean, broadening the benefits of these traits across different agricultural sectors [5] Company Overview - Cibus is a technology company focused on gene editing to develop and license traits to seed companies, addressing productivity and sustainability challenges in agriculture, with an estimated global economic impact of $300 billion annually due to diseases and pests [5] - The company has a pipeline of five productivity traits, including those for weed management in rice and disease resistance, with a long-term focus on major global row crops such as canola, rice, and soybean [5]